We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Strength Seen in Alexion Pharmaceuticals (ALXN): Stock Soars 14.5%
Read MoreHide Full Article
Alexion Pharmaceuticals, Inc. was a big mover last session, as the company saw its shares rise more than 14% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. The stock picked up sharply from the near-flat trend of $106.04 to $113.46 in the past one month time frame.
The move came after the company reported solid first-quarter 2018 results. Also, the company’s announcement of the Phase 3 study of its C5 complement inhibitor ALXN1210, verified that patients with paroxysmal nocturnal hemoglobinuria disease can safely switch from Soliris.
The company has not seen any estimate revisions over the past month, while the Zacks Consensus Estimate for the current quarter also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Alexion currently has a Zacks Rank #2 (Buy), while its Earnings ESP is positive.
Is ALXN going up? Or down? Predict to see what others think: Up or Down
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
Strength Seen in Alexion Pharmaceuticals (ALXN): Stock Soars 14.5%
Alexion Pharmaceuticals, Inc. was a big mover last session, as the company saw its shares rise more than 14% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. The stock picked up sharply from the near-flat trend of $106.04 to $113.46 in the past one month time frame.
The move came after the company reported solid first-quarter 2018 results. Also, the company’s announcement of the Phase 3 study of its C5 complement inhibitor ALXN1210, verified that patients with paroxysmal nocturnal hemoglobinuria disease can safely switch from Soliris.
The company has not seen any estimate revisions over the past month, while the Zacks Consensus Estimate for the current quarter also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Alexion currently has a Zacks Rank #2 (Buy), while its Earnings ESP is positive.
Alexion Pharmaceuticals, Inc. Price
Alexion Pharmaceuticals, Inc. Price | Alexion Pharmaceuticals, Inc. Quote
Investors interested in the Medical - Biomedical and Genetics industry may consider Bellerophon Therapeutics, Inc. (BLPH - Free Report) , which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is ALXN going up? Or down? Predict to see what others think: Up or Down
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>